Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beigene Ltd ADR
(NQ:
BGNE
)
218.97
+6.58 (+3.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beigene Ltd ADR
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Week In Review: Shanghai CARsgen To Raise $400 Million In Hong Kong IPO
June 12, 2021
Shanghai CARsgen Therapeutics is staging an IPO on the Hong Kong Exchange that could raise $400 million to support development of the company's CAR-T portfolio. The shares are scheduled to begin...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
BeiGene Touts Initial Brukinsa Efficacy, Safety Profile For Leukemia, Compared To Imbruvica
June 11, 2021
BeiGene Ltd (NASDAQ: BGNE) revealed an interim analysis of the Phase 3 ALPINE trial evaluating Brukinsa (zanubrutinib) to Johnson & Johnson’s (...
Via
Benzinga
BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021
June 11, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia
June 11, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene, Shoreline Biosciences Ink Development Pact For NK Cell Therapies In Cancer
June 09, 2021
Shoreline Biosciences Inc and BeiGene Ltd (NASDAQ: BGNE) have announced an exclusive worldwide strategic collaboration to develop and commercialize a...
Via
Benzinga
Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies
June 09, 2021
From
BeiGene, Ltd.
Via
Business Wire
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
June 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc...
Via
Benzinga
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors
June 07, 2021
From
BeiGene, Ltd.
Via
Business Wire
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
June 07, 2021
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...
Via
Benzinga
Exposures
Product Safety
BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting
June 04, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting
June 04, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021
June 01, 2021
From
BeiGene, Ltd.
Via
Business Wire
Week In Review: LianBio Acquires Two IBD Candidates In $218 Million Deal
May 22, 2021
LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. The $218 million deal includes $18 million upfront and $200...
Via
Talk Markets
BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck Cancer
May 21, 2021
BeiGene Ltd (NASDAQ: BGNE) has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a...
Via
Benzinga
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
May 21, 2021
From
BeiGene, Ltd.
Via
Business Wire
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
May 31, 2021
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-...
Via
Benzinga
Exposures
Product Safety
BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting
May 19, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene's Brukinsa US Application For Expanded Use Under FDA Review
May 19, 2021
The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application for Brukinsa (zanubrutinib) for marginal zone lymphoma (MZL)...
Via
Benzinga
Exposures
Product Safety
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma
May 19, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress
May 12, 2021
From
BeiGene, Ltd.
Via
Business Wire
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines
May 08, 2021
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine...
Via
Talk Markets
Exposures
COVID-19
China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer
May 07, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Reports First Quarter 2021 Financial Results
May 06, 2021
From
BeiGene, Ltd.
Via
Business Wire
This Is Why Humira Isn't AbbVie's Biggest Problem Right Now
May 03, 2021
Two of AbbVie's most important assets could get a lot harder to sell.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
A Heavy News Day And Crypto
April 28, 2021
Israeli TEVA reported Q1 sales which missed forecasts at $4 bn, leading to a 2.6% drop in its price earlier today.
Via
Talk Markets
BeiGene's Stock Is Trading Higher As Brukinsa Drug On Par With JNJ's Imbruvica In Late-Stage Blood Cancer Studies
April 28, 2021
BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against...
Via
Benzinga
BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia
April 28, 2021
From
BeiGene
Via
Business Wire
Exceptions To A Low Period
April 25, 2021
This past week served as a negative period for my stock holdings, with a couple of exceptions. Here I discuss what those exceptions were and how they moved.
Via
Talk Markets
Currency Manipulation
April 16, 2021
London's FTSE 100 index today rose over 7000 for the first time in 14 months. It hit 7019.53.
Via
Talk Markets
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
April 12, 2021
From
BeiGene, Ltd.
Via
Business Wire
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.